论文部分内容阅读
目的了解既往单采浆人群中HIV/HCV共感染的流行特征;HCV合并感染对HIV感染者的影响;评估抗逆转录病毒治疗的效果。方法对既往单采浆献血员及其密切接触者进行回顾性调查,检测HIV抗体、HCV抗体。并用χ2检验比较病死率和生存率。结果HIV/HCV共感染与单独HIV感染者的发病率差异有统计学意义(P<0.001)。抗病毒治疗前后病死率差异有统计学意义(P<0.001)。HIV/HCV共感染与HIV单独感染者的病死率差异无统计学意义(P>0.05)。结论HIV/HCV共感染可能增加HIV感染者发病的危险。对HIV/HCV共感染者给予更多关注。实施干预措施可以有效降低患者的病死率。应对艾滋病患者积极开展抗逆转录病毒治疗。
Objectives To understand the prevalence of co-infection with HIV / HCV in previously plasmatized individuals; the impact of HCV coinfection on HIV-infected individuals; and to assess the efficacy of antiretroviral therapy. Methods A retrospective study was conducted on past single blood plasma donors and their close contacts to detect HIV antibody and HCV antibody. Chi-square test was used to compare mortality and survival rate. Results The incidence of HIV / HCV co-infections was significantly different from that of HIV-infected individuals (P <0.001). There was significant difference in the mortality rate before and after antiviral therapy (P <0.001). There was no significant difference in the case fatality rate between HIV / HCV co-infections and those infected with HIV alone (P> 0.05). Conclusions HIV / HCV co-infection may increase the risk of HIV infection. Give more attention to HIV / HCV co-infected. The implementation of interventions can effectively reduce the patient’s case fatality rate. Actively carry out antiretroviral therapy for people with AIDS.